Proposal for Latiglutenase (ALV003)

Overview of Therapeutic Candidate:
Latiglutenase (ALV003) is an investigational enzyme therapy developed for the treatment of celiac disease. It is a recombinant formulation that combines two distinct gluten-specific proteases—one derived from germinating barley (a cysteine endoprotease, often referred to as EP‐B2) and a second prolyl endopeptidase (PEP) from microbial sources such as Sphingomonas capsulata. These enzymes are produced by recombinant DNA technology, ensuring consistent activity and purity. As an enzymatic therapy, ALV003 belongs to the class of glutenases, agents designed to enzymatically digest gluten peptides into smaller, less immunogenic fragments. The concept behind this approach draws on the observation that mammalian gastrointestinal proteases cannot fully cleave proline- and glutamine-rich gliadin peptides, which then trigger the pathogenic immune response in genetically predisposed individuals. Historically, enzyme-based therapies have been used to supplement or replace deficient digestive enzymes in conditions like lactose intolerance, but in the case of celiac disease, the goal is to degrade immunotoxic peptides before they can breach the epithelial barrier (Caio et al., 2020; Lähdeaho et al., 2014).

Therapeutic History:
The rationale for ALV003 emerged from preclinical studies demonstrating that gluten peptides, especially the 33-mer peptide known for its robust immunogenicity, resist degradation by endogenous proteases and are central to celiac disease pathogenesis. Early in vitro studies showed that the combination of a barley-derived cysteine protease and a microbial prolyl endopeptidase could degrade more than 90% of immunoreactive gluten epitopes under simulated gastric conditions. This promising biochemical activity led to a series of early-phase clinical trials. Phase 0 and Phase 1 studies examined safety and pharmacodynamics in healthy volunteers and patients with well-controlled celiac disease; these trials established that ALV003 was generally safe and well tolerated when administered orally with gluten-containing meals (ClinicalTrials.gov, 2008; Lähdeaho et al., 2014). Phase 2a and 2b studies subsequently evaluated its ability to protect against gluten-induced mucosal injury in patients on a gluten-free diet, particularly during controlled gluten challenge periods. Although results on symptomatic improvement were sometimes mixed, several studies provided evidence that ALV003 could attenuate histological damage, as measured by preservation of the villous height-to-crypt depth ratio and reduction in intraepithelial lymphocyte counts (Lähdeaho et al., 2014; Kurppa et al., 2014). While ALV003 has not yet reached the stage of regulatory approval or widespread clinical use for celiac disease, its history in clinical trials has established its feasibility as an adjunct to the gluten-free diet and validated its underlying biochemical mechanism (ClinicalTrials.gov, 2009; ClinicalTrials.gov, 2010).

Mechanism of Action:
The mechanism of action of Latiglutenase is grounded in its dual proteolytic system that targets the specific biochemical features of immunotoxic gluten peptides. Gluten proteins, particularly gliadins, contain sequences that are rich in proline and glutamine residues; these features render them resistant to degradation by human digestive enzymes. The therapeutic design of ALV003 addresses this problem in two sequential steps. First, the cysteine endoprotease component (derived from barley) cleaves gluten peptides at glutamine residues, thereby destabilizing the larger peptide structures and exposing additional cleavage sites. Second, the prolyl endopeptidase from Sphingomonas capsulata further hydrolyzes the newly exposed proline-rich sequences, effectively reducing the peptide size and consequently its immunogenic potential (Caio et al., 2020; Lähdeaho et al., 2014).

At the molecular level, this enzymatic cleavage disrupts the intact immunodominant sequences—such as the well-studied 33-mer peptide in gliadin—which are known to be presented by antigen-presenting cells in the context of HLA-DQ2/DQ8 molecules. In doing so, ALV003 prevents the subsequent activation of gluten-specific CD4+ T cells, thereby limiting the inflammatory cascade that leads to mucosal damage. Beyond direct peptide cleavage, recent hypotheses suggest that by decreasing the load of immunogenic peptides reaching the intestinal mucosa, ALV003 might reduce the activation of the CXCR3 chemokine receptor pathway. In patients with celiac disease, activation of CXCR3 is linked to the release of the protein zonulin, a key regulator of intestinal tight junction integrity. Thus, by degrading gluten peptides before they trigger this cascade, ALV003 could reduce zonulin release, maintain transepithelial electrical resistance (TEER), and ultimately prevent cytokine-driven tight junction disruption (Syage et al., 2019; Kurppa et al., 2014). Although the direct modulation of zonulin is an emerging aspect of its proposed mechanism, the primary, well-documented biochemical activity remains the enzymatic cleavage of gliadin peptides (Freeman, 2015; Kivelä et al., 2021).

Expected Effect:
Given its dual-enzyme composition and robust in vitro activity, the expected effect of ALV003 in the proposed assay—and ultimately in clinical application—is the effective degradation of immunotoxic gliadin peptides in the gastrointestinal lumen. In an organoid assay or ex vivo intestinal model, the treatment with Latiglutenase is anticipated to lead to several interrelated outcomes. First, the degradation of gluten peptides should result in a measurable reduction in the pool of intact immunogenic peptides available to trigger an immune response. This reduction is expected to attenuate the release of zonulin—a peptide hormone that increases intestinal permeability by modulating tight junction proteins—and consequently preserve TEER in epithelial cultures (Nemteanu et al., 2022; Syage et al., 2019).

Subsequently, by preventing the crossing of immunogenic peptides into the lamina propria, ALV003 should decrease the activation of gluten-specific CD4+ T cells, leading to a decreased secretion of pro-inflammatory cytokines such as interferon-gamma (IFN-γ) and interleukin-15 (IL-15). This reduction in cytokine production could further contribute to maintaining intestinal mucosal integrity and reduce the ensuing inflammatory damage typically observed in celiac disease. In vitro results from organoid assays and ELISpot studies have shown that gluten-degrading enzymes can indeed reduce markers of immune activation, suggesting that treatment with ALV003 may have both histological and symptomatic benefits in patients (Pérez et al., 2012; Lähdeaho et al., 2014). Furthermore, in a clinical context where seropositive patients—those with ongoing immune activation despite a gluten-free diet—are treated, post hoc analyses from trials have indicated dose-dependent improvements in gastrointestinal symptoms such as abdominal pain and bloating (Syage et al., 2019). Therefore, the expected outcome of administering ALV003 is the dual benefit of protecting the intestinal mucosa via biochemical degradation of gluten peptides and preserving barrier integrity through the modulation of zonulin release, ultimately resulting in symptom relief and improved quality of life for patients with celiac disease (Massironi et al., 2024; Kivelä et al., 2021).

Overall Evaluation:
Evaluating the potential of ALV003 as a therapeutic candidate for celiac disease reveals several noteworthy strengths alongside some limitations. On the positive side, ALV003 is rooted in a strong mechanistic rationale. It specifically targets the primary trigger of celiac pathology—immunogenic gluten peptides—by utilizing a combination of enzymes that act synergistically to degrade sequences that are otherwise resistant to human proteases. This precise biochemical strategy not only reduces the antigenic load but also decreases subsequent immune activation, potentially leading to reduced zonulin release and preservation of tight junction integrity. Such an approach is particularly innovative as it addresses both the biochemical and barrier-disrupting aspects of gluten-induced pathology (Caio et al., 2020; Lähdeaho et al., 2014).

Moreover, Latiglutenase has undergone extensive preclinical and early-phase clinical evaluation. Multiple phase 1 and phase 2 studies have demonstrated its safety and bioactivity in controlled gluten challenge settings, showing histological evidence of reduced mucosal damage despite gluten exposure. This clinical history supports its feasibility and potential as an adjunct therapy to improve outcomes in patients who, despite adherence to a gluten-free diet, suffer from inadvertent gluten exposure and its consequences (Kurppa et al., 2014; ClinicalTrials.gov, 2008).

However, some challenges remain. Clinical trial data have been variable, particularly regarding symptomatic improvement, with some studies failing to demonstrate statistically significant benefits on patient-reported outcomes in the general celiac population. It appears that the benefit of ALV003 may be most pronounced in seropositive subgroups, indicating that its efficacy may depend on the extent of ongoing immune activation and gluten exposure in a given patient. Furthermore, ensuring that the enzyme retains sufficient activity in the highly acidic gastric environment is a critical formulation challenge. Gastric acid and the presence of other proteases may diminish the activity of ALV003, potentially limiting its capacity to completely degrade all immunogenic peptides if dosing or formulation is not fully optimized. Thus, while the biochemical rationale is robust, translational effectiveness in achieving consistent and clinically meaningful endpoints such as mucosal healing and symptomatic relief remains an area for further investigation (Massironi et al., 2024; Nemteanu et al., 2022).

Another consideration is that ALV003 is intended to act as an adjunct to a gluten-free diet rather than a replacement therapy. Its clinical utility is therefore limited to mitigating the effects of inadvertent gluten contamination, which, while a significant problem, does not entirely remove the burden of dietary vigilance from patients. Nonetheless, for those patients who experience accidental gluten exposure and consequent mucosal damage or symptoms, ALV003 represents a promising approach that could improve quality of life and reduce long-term complications (Syage et al., 2019; Pérez et al., 2012).

In summary, ALV003 shows considerable promise as a therapeutic candidate for celiac disease based on its targeted enzymatic design, proven biochemical activity, and established safety profile in early clinical trials. Its mechanism of degrading proline-rich gliadin peptides directly addresses the key pathogenic event in celiac disease, and its potential to reduce zonulin-mediated tight junction disruption offers an innovative barrier-protective effect. Strengths include its rational design, supportive preclinical data, and safety demonstrated in human trials, while weaknesses relate to the variability in clinical symptom endpoints, potential issues with enzymatic stability in vivo, and the fact that it currently serves only as an adjunct to dietary management rather than a standalone treatment. Overall, further clinical validation with optimized dosing strategies and improved formulations is warranted to fully realize its potential as a complement to the gluten-free diet in managing celiac disease (Freeman, 2015; Kivelä et al., 2021; Kurppa et al., 2014).

References:

Caio, G., Ciccocioppo, R., Zoli, G., De Giorgio, R., & Volta, U. (2020). Therapeutic options for coeliac disease: What else beyond gluten-free diet? Digestive and Liver Disease, 52, 130–137. https://doi.org/10.1016/j.dld.2019.11.010

ClinicalTrials.gov. (2008). Effects of Gluten Digestion With ALV003 (NCT00859391). Retrieved from https://clinicaltrials.gov/ct2/show/NCT00859391

ClinicalTrials.gov. (2009). Safety and Efficacy of ALV003 for the Treatment of Celiac Disease (NCT00959114). Retrieved from https://clinicaltrials.gov/ct2/show/NCT00959114

ClinicalTrials.gov. (2010). Safety and Efficacy of Varying Methods of ALV003 Administration for the Treatment of Celiac Disease (NCT01255696). Retrieved from https://clinicaltrials.gov/ct2/show/NCT01255696

Freeman, H. J. (2015). Emerging drugs for celiac disease. Expert Opinion on Emerging Drugs, 20, 129–135. https://doi.org/10.1517/14728214.2015.985204

Kivelä, L., Caminero, A., Leffler, D. A., Pinto-Sanchez, M. I., Tye-Din, J. A., & Lindfors, K. (2021). Current and emerging therapies for coeliac disease. Nature Reviews Gastroenterology & Hepatology, 18, 181–195. https://doi.org/10.1038/s41575-020-00378-1

Kurppa, K., Hietikko, M., Sulic, A.-M., Kaukinen, K., & Lindfors, K. (2014). Current status of drugs in development for celiac disease. Expert Opinion on Investigational Drugs, 23, 1079–1091. https://doi.org/10.1517/13543784.2014.916274

Lähdeaho, M.-L., Kaukinen, K., Laurila, K., Vuotikka, P., Koivurova, O.-P., Kärjä-Lahdensuu, T., Marcantonio, A., Adelman, D. C., & Mäki, M. (2014). Glutenase ALV003 attenuates gluten-induced mucosal injury in patients with celiac disease. Gastroenterology, 146, 1649–1658. https://doi.org/10.1053/j.gastro.2014.02.031

Massironi, S., Franchina, M., Elvevi, A., & Barisani, D. (2024). Beyond the gluten-free diet: Innovations in celiac disease therapeutics. World Journal of Gastroenterology, 30, 4194–4210. https://doi.org/10.3748/wjg.v30.i38.4194

Nemteanu, R., Ciortescu, I., Hincu, C. E., Clim, A., Gheorghe, L., Trifan, A., & Plesa, A. (2022). Replacing the burden of the gluten free diet: Then, now, and the future. International Journal of Molecular Sciences, 23, 15108. https://doi.org/10.3390/ijms232315108

Pérez, L. C., Castillejo de Villasante, G., Cano Ruiz, A., & León, F. (2012). Non-dietary therapeutic clinical trials in coeliac disease. European Journal of Internal Medicine, 23, 9–14. https://doi.org/10.1016/j.ejim.2011.08.030

Syage, J. A., Green, P. H. R., Khosla, C., Adelman, D. C., Sealey-Voyksner, J. A., & Murray, J. A. (2019). Latiglutenase treatment for celiac disease: Symptom and quality of life improvement for seropositive patients on a gluten-free diet. GastroHep, 1, 293–301. https://doi.org/10.1002/ygh2.371
